AR and breast cancer: Since controversial observations about AR oncogenic (48, 49) rather than tumor suppressor (50, 51) function in BC do exist, investigating the crosstalk between AR and ncRNAs may provide further insights into the role of AR signaling in AR+ BC, and unravel novel molecular features to take into account before planning an anti-AR therapy.